Tarlatamab Phase 3 Results: New SCLC Standard at ASCO 2025Explore the DeLLphi-304 study at ASCO 2025: tarlatamab offers 13.6 months median survival vs 8.3 months with chemotherapy in relapsed SCLC. Learn more!
Publisher of over 50 scientific journals across the life, physical, earth, and health sciences, both independently and in partnership with scientific societies including Cell, Neuron,…
Guide to post-CDK4/6 inhibitor treatment for HR+/HER2- breast cancer. Learn resistance, therapies, and access with ASCO expertise.
Discover insights from the MATTERHORN trial, showcasing the impact of durvalumab combined with FLOT chemotherapy.
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
See how the FDA’s new voucher program impacts oncology drug approvals, focusing on speed and safety. Tailored for ASCO.org viewers.
Explore HR+/HER2- metastatic breast cancer 2L outcomes with crucial insights from ASCO 2025 on median progression-free survival.
Discover BsAb oncology & 2025 clinical trials. Explore bispecific antibodies cancer therapy on OncologyTube.com. Watch now!
Explore how China oncology trials are revolutionizing cancer research with a remarkable increase in clinical trials.
Explore HCC treatment selection with guidelines from ASCO 2025 to improve patient outcomes and management of hepatocellular carcinoma.
FDA approves taletrectinib for ROS1-positive NSCLC on June 11, 2025. Learn about trial results, dosage, and side effects in this easy guide.
